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Abstract Background A clinical medication review,
including patient involvement, is expected to improve
pharmaceutical care. Objective To determine whether a
clinical medication review followed by a pharmaceutical
care plan decreases the number of potential drug-related
problems (DRPs) and pharmaceutical care issues (PCIs)
and leads to a positive effect on relevant clinical and lab-
oratory parameters for elderly cardiovascular patients with
multiple drug use. Setting Randomized controlled trial in
eight primary care settings in the Netherlands. Method
Elderly polypharmacy patients with a cardiovascular dis-
order were randomized into two groups. Intervention
patients received a clinical medication review, followed by
a pharmaceutical care plan developed in cooperation
between these patients’ pharmacists and general practi-
tioners (GPs), and agreed to by the patients. Control
patients received care as usual. Patient data were collected
at the start of the study (t = 0) and after 1-year follow-up
(t = 1). Main outcome measure Decrease in potential
DRPs and pharmaceutical PCIs, improvement of clinical
and laboratory parameters. Results 512 patients were
included. An average of 2.2 potential DRPs and pharma-
ceutical PCIs were defined per patient in the intervention
group. After 1-year follow-up, 47.2 % of potential DRPs
and PCIs were resolved. In total, 156 care interventions
were proposed (0.9/patient), 108 of which were imple-
mented after 1 year (69.2 %). For control-group patients, a
total of 47 proposed care interventions were documented
for 255 patients (0.2/patient); after 1 year, 43 had been
implemented (91.5 %). The study intervention (p\ 0.001)
and the number of medicines used (p = 0.030) had a sig-
nificant effect on the number of interventions proposed.
Small biochemical changes in cardiovascular risk factors
did occur, but the differences were small and not consid-
ered clinically relevant. Conclusion The integrated use of a
clinical medication review with a pharmaceutical care plan
in a primary care setting supports the detection of and
decrease in DRPs and pharmaceutical PCIs in almost half
of the patients. Its benefit in terms of control of cardio-
vascular risk factors and safety parameters was relatively
low. Risk stratification might be necessary to decide which
patients might benefit most from this type of intervention.
Keywords Community pharmacy  Netherlands 
Pharmaceutical care  Pharmacist consultation  Pharmacy
practice  Polypharmacy  Safety
Impacts of findings on practice statements
• Risk stratification is important in order to define
patients who benefit most from the intervention;
• Besides the appropriate knowledge, sufficient time and
reimbursement are important to implement clinical
pharmacy services in daily practice.
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Introduction
Appropriate prescribing in elderly people needs more
attention [1]. The number of medications taken may affect
quality of prescribing and adherence in older persons [2, 3].
A regular medication review (MR) has the potential to
improve pharmaceutical care in patients [4, 5]. This type of
review is defined as ‘‘a structured, critical examination of a
patient’s medicines with the objective of reaching an
agreement with the patient about treatment, optimizing the
impact of medicines, minimizing the number of medica-
tion-related problems and reducing waste’’ [6]. Only a
clinical medication review (CMR), including pharmacist,
general practitioner (GP), and patient [6], can be expected
to improve pharmaceutical care [4]. Patient involvement is
important both for the identification of drug-related prob-
lems (DRPs) [7] and for the long-term success of the
intervention performed [4].
Various MR methods have been described. Clinical
pharmacists are able to review care-home patients’ medi-
cation and make recommendations to GPs [8]. A decrease
in DRPs was shown after a pharmacist-conducted MR of
elderly patients receiving medicines via automated dis-
pensing machines [9]. In a hospital setting, it was con-
cluded that structured pharmaceutical care, according to a
protocol, leads to more changes in drug therapy compared
to care as usual [10]. A CMR intervention, including
pharmacists, GPs, and patients, has demonstrated that such
an intervention may prevent medication-related hospital
admissions but without any statistically significant effect
on the number of adverse drug events, quality of life, or
survival [11, 12]. Assessment of a patients’ pharma-
cotherapy includes checking whether all indications are
treated appropriately, whether the medication treatment is
effective and safe, and whether a patient has adhered to the
proposed therapy. Potential problems concerning pharma-
cotherapy can be defined as a potential DRP, based on the
concept of Cipolle et al. [13], or on the basis of a phar-
maceutical care issue (CI) [11]. Literature defines different
sub-groups of patients with known non-adherence and/or
medication problems [14, 15]. Methods for enhancing
medication safety in older persons may be directed towards
aspects of specific types of drugs, such as anticholinergic
drug burden, under-prescribing, or the use of the Medica-
tion Appropriateness Index, Beers criteria, or the STOPP
and START criteria [16–20]. Elderly patients with a car-
diovascular disorder use multiple medicines that require
regular monitoring using relevant clinical and laboratory
parameters related to cardiovascular risk assessment (blood
pressure and cholesterol levels) and safety (renal function
and potassium). This patient population could benefit from
a CMR [15] with adequate follow-up and was therefore
chosen as our study population. Compared to other studies,
we combined a CMR with a web-based pharmaceutical
care plan (W-PCP) to facilitate integrated care and to
systematically structure joint use of patients’ medical and
pharmaceutical records and to document the integrated
information and interventions for follow-up. Moreover, we
performed this study in daily practice, and not in a research
setting, so that healthcare providers could implement the
intervention as realistic as possible in their daily routine.
Aim of the study
To determine whether a CMR followed by a pharmaceu-
tical care plan (PCP) decreases potential DRPs and PCIs,
along with a positive effect on cardiovascular risk factors
and safety parameters for elderly polypharmacy patients
with a cardiovascular disorder.
Ethics approval
An independent Ethics Committee (RTPO/Leeuwarden, the
Netherlands) reviewed the study protocol. The protocol was
graded as a clinical intervention study with no risk for patients.
To guarantee patient privacy, patient data were made anony-
mous before the database was provided to the researchers.
Method
A randomized controlled trial was performed in the pri-
mary care setting of the Netherlands. Community phar-
macists (n = 500; 25 % of all pharmacies in the
Netherlands) were invited by letter to participate. Phar-
macies were randomly selected in an area defined by the
sponsor of the study. After consenting, the pharmacists
subsequently contacted GPs and asked for their participa-
tion. Good cooperation between pharmacists and GPs, and
the willingness to share patient data were prerequisites.
Participating pharmacies and GP practices were connected
to a newly developed W-PCP application [21]. This web-
based application uploaded all patient data from pharmacy
and GP computer systems in order to combine information
about diagnoses, medicines prescribed, and clinical and
laboratory parameters in one patient file, accessible to both
patient’s pharmacist and GP. Patients were included based
on inclusion criteria from screening pharmacy records:
• aged C60 years;
• elderly patients with polypharmacy (five or more
medicines for chronic use);
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• of which at least one medicine for a cardiovascular
disorder (ATC class C [22]).
Patients who did not speak Dutch language or who were
mentally impaired were excluded.
Patient inclusion transpired between August 2009 and
June 2010. After informed consent, patients were ran-
domized into an intervention or a control group. Ran-
domization occurred based on unique patient identification
numbers (IDs) in the pharmacy computer system (odd
number: intervention group; even number: control group).
Intervention patients received an invitation to consult their
pharmacist for a CMR. The PCP was subsequently devel-
oped in cooperation between patient’s pharmacist and GP,
and agreed to by the patient. Each evaluation of the PCP
for intervention patients consisted of three components: (1)
potential DRPs and PCIs, (2) proposed care interventions
to reach treatment goals, and (3) implemented care inter-
ventions. Patients from the control group received care as
usual and were not treated differently than before. All
patients were followed-up for 1 year. Total study period
per site was 18 months, with consultations and MRs per-
formed during the first 6 months. The last data collection
finished in December 2011.
Support
A learning module of the W-PCP application was provided
by the researchers to all participating pharmacists and GPs.
During the study period technical assistance was available.
All participating pharmacists received a 1-day training
course on communication skills with GPs and patients.
Additional written information about performing a CMR
was provided. During the study period, researchers visited
study sites regularly in order to monitor the time schedule
of the study and provide assistance.
Data collection
Patient data were uploaded regularly, depending upon
patients’ consultations, and collected in the W-PCP appli-
cation. Two measurements were performed, one at the
beginning of the study (t = 0) and one after 1-year follow-
up (t = 1). Patient data consisted of general patient infor-
mation (age, gender), episodes (ICPC-coded [23]),
medicines dispensed (ATC-coded [22]), and clinical and
laboratory parameters. Patient data was provided to the
researchers in a database (Microsoft Access 2010).
Primary outcome of this study was a decrease in
potential DRPs and PCIs, expressed as a percentage of
resolved DRPs and PCIs. Secondary outcome was the
differences in clinical and laboratory parameters. PCPs
consisted of ‘‘free text’’ entered by the healthcare
providers. Two researchers (MG, author, and EM, not an
author) coded all individual care plans independently. All
codes were compared and inconsistencies discussed until
agreement was reached. For control-group patients, infor-
mation on care interventions was collected retrospectively.
Sample size calculation and analysis
Two sample size calculations were performed. Our aim
was to demonstrate a 25 % decrease in potential DRPs and
PCIs. Based on a paired means power analysis using sim-
ulation and Wilcoxon signed-rank test using alpha = 0.05
and a power of 0.80, we needed 13 patients per pharmacy
in the intervention group. The second aim was to demon-
strate a 10 % improvement in clinical and laboratory
parameters. Based on a two independent proportions power
analysis using alpha = 0.05 and a power of 0.80, we
needed 400 patients for each group. Our aim was to recruit
patients from 10 to 12 study sites. Based on our second
sample size calculation, and considering dropouts as a
consequence of losses to follow-up, our aim was to include
100 patients per study site.
Statistical analyses were performed using SPSS 21,
Mplus 7.1, and SAS 9.3. Differences in patient character-
istics were calculated using 1-way ANOVA and Pearson
Chi square test. Multilevel analysis was used to analyze the
nesting structure. Effects of the study intervention on
number of care interventions performed were analyzed
using a two level Multilevel analysis with Poisson regres-
sion analysis, where patients (level 1) were nested within
GPs (level 2). As model information, we used the Akaike
information criteria (AIC) and the Bayesian information
citeria (BIC) to compare the relative goodness-of-fit of the
presented models. Effect of the study intervention on
clinical endpoints was analyzed using a three level Mul-
tilevel analysis, including measurements (t = 0 and t = 1)
(level 1) nested within patients (level 2) and patients nested
within GPs (level 3). Results were considered statistically
significant at a significance level p\ 0.05.
Results
Eight study sites recruited 512 patients: 248 in the inter-
vention group, 264 in the control group. Pharmacists and
GPs did not manage to perform CMRs for all intervention
patients during the study period due to time limitations.
Therefore, 70 patients, originally randomized into the
intervention group, were analyzed as a separate group since
they did not receive any part of the intervention (Fig. 1).
Patient characteristics were comparable between groups
(Table 1).
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In total, 394 potentially harmful DRPs and PCIs were
defined for 178 intervention patients (2.2/patient). After
1-year follow-up, 186 potential DRPs and PCIs (47.2 %)
were resolved; 208 DRPs and PCIs (1.2/patient) were not
resolved or with unknown outcome from the available data.
During the study period, 156 care interventions were pro-
posed (0.9/patient) (range 0–5 per patient) of which 108
were implemented after 1 year (69.2 %). Figure 2 shows
the number of proposed and implemented care interven-
tions per category. Most proposed care interventions were
related to drug-taking/adherence, monitoring (e.g., addi-
tional clinical values), and unnecessary drug therapy.
Categories with the most implemented interventions:
unnecessary drug therapy (e.g., stop medicine) (91.7 %),
dosage too low (e.g., increase dosage) (90.0 %), and
dosage too high (e.g., decrease dosage) (80.0 %).
In the control group, a total of 47 proposed care inter-
ventions were documented for 255 patients (0.2/patient)
(range 0–4 per patient). Information was missing for 9
patients. Of the 47 proposed care interventions, 43 were
implemented after 1 year (91.5 %).
Six different models analyzed the effect on the number
of care interventions proposed. The effect of the study
intervention (model 1), age and gender (model 2), number
of medicines (model 3), number of episodes (model 4), all
independent variables (model 5), and the study intervention
together with number of medicines (model 6). The study
intervention and the number of medicines showed a sig-
nificant effect on the number of care interventions pro-
posed. Table 2 shows the effect of models 5 and 6.
Looking at the differences between models 5 and 6, AIC
and BIC were lower for model 6 and thus considered
preferable. According to Raftery [24] a difference of over
10 between the BIC of models 5 and 6 is associated as
‘‘very strong’’ evidence.
Table 3 shows the effect of the study intervention on
cardiovascular risk factors and safety parameters. Inter-
vention patients had a significantly decreased diastolic
Patient letters sent (n = 2102)
Excluded  (n = 1590)
♦ Declined to participate
Allocated to intervention group (n = 248) Allocated to control group (n = 264)




Did not receive 
intervention
(n = 70)
Received care as 
usual
(n = 264)
Fig. 1 Patient recruitment and
randomization
Table 1 Patient characteristics (n = 512) at time of inclusion (t = 0)
Intervention patients with intervention
n = 178 [mean (SD)]
Intervention patients without
intervention n = 70 [mean (SD)]
Control n = 264
[mean (SD)]
p value
Age (years) 72.5 (7.735) 71.8 (8.372) 73.1 (7.797) 0.433c
Gender, male (%) 46.1 52.9 47.3 0.622d
# Medicinesa 8.3 (2.721) 8.0 (3.277) 7.9 (2.926) 0.591c
# Episodesb 14.6 (8.210) 14.3 (6.475) 14.8 (8.683) 0.891c




d Pearson Chi square test
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blood pressure after 1-year follow-up (79.8–76.8 mmHg;
p = 0.008). HDL-cholesterol showed a small but signifi-
cant increase in two groups (intervention patients with
intervention: 1.29–1.37 mmol/L; p = 0.021; intervention
patients without intervention: 1.26–1.37 mmol/L;
p = 0.039). LDL-cholesterol showed a small but signifi-
cant decrease in the control group (2.61–2.58 mmol/L;
p = 0.032). Other parameters showed no significant effect.
Discussion
A CMR followed by a PCP resolves almost 50 % of
potential harmful DPRs and PCIs (1.0/patient). Differences
in percentages of care interventions implemented were
observed in different categories. Higher percentages were
found for ‘‘easy to implement’’ interventions like stopping
a medicine or adjusting a dosage. Interventions from cat-
egories taking more time, for example, ‘‘additional drug
therapy required’’, were implemented less frequently. Per
patient, an average of 2.2 potential harmful DRPs and PCIs
were formulated in the PCP. This is less compared to other
studies. In a similar study, 3.5 DRPs and PCIs per patient
were found [12], and, after a MR in patients using an
automated drug-dispensing system, even a mean of 8.6
potential DRPs per patient was observed [9]. A reason for
the lower number of DRPs and PCIs in our study could be
the fact that patients seemed well monitored—looking at
the initial clinical and laboratory values (Table 3)—and
this should be seen in the context of the very low incidence
of proposed care interventions in the control group
(0.2/patient).
Furthermore, less skill and experience in performing a
CMR on the part of primary healthcare providers could
Fig. 2 Number of proposed and
implemented interventions
based on DRPs/PCIs retrieved
from the pharmaceutical care
plan (n = 178). DRP drug
related problem, CI care issue
Table 2 Effect of independent
variables on number of care
interventions proposed
(n = 433 patients)
Model 5 Model 6
Estimate SE p valuec Estimate SE p valuec
Study intervention 1.657 0.317 \0.001* 1.662 0.317 \0.001*
Age 0.005 0.013 0.723
Gender -0.158 0.142 0.265
# Medicinesa 0.045 0.023 0.049* 0.055 0.025 0.030*




SE, standard error; #, number; AIC, Akaike information criteria; BIC, Bayesian information criteria
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have influenced our findings. It is important to have a
patient interview as part of the MR process in order to
define DRPs [4, 7]. For this reason, pharmacists received a
1-day training course in communication skills and addi-
tional written information about how to perform a CMR.
More intensive training and experience might help phar-
macists perform a CMR better and so define more DRPs.
Another reason could be a selection bias, because com-
munity pharmacists who had a good relationship with their
GPs were recruited, which could have had a positive effect
on the quality of medication therapy management. In
addition, our study was conducted in regular pharmacies
and thereby could reflect regular daily practice more than
in studies entailing an extensive training course for phar-
macists [11, 12] or with MRs performed by independent
pharmacists with several years of experience in performing
MRs [9].
Data on interventions performed on control-group
patients were collected retrospectively and included only
those care interventions where the pharmaceutical care
problem was actively documented as a potential DRP and/
or CI. A change in medication without a specific docu-
mented reason was not included in our data. Therefore,
these data might underestimate the number of care inter-
ventions for control-group patients and specifically pro-
posed interventions that were not implemented. In daily
practice, we expect that, when a pharmacist proposes an
intervention to a patient’s GP, not all the proposed inter-
ventions will be actively documented in the patient file,
especially when the GP and/or patient does not agree with
the intervention. Many medication changes occur during a
patient’s treatment, but the reason for a care intervention is
not always documented.
The second objective of our study, related to the patient
efficacy outcome in terms of improvement in cardiovas-
cular risk factors, showed small biochemical changes. It
should be noted that baseline clinical and laboratory
parameters already showed acceptable values, so the room
for improvement was small. Biochemical changes did
occur, including changes in HDL- and LDL-cholesterol,
but differences were small and not considered clinically
relevant. We performed this study in primary care settings
with a certain level of cooperation between pharmacists
and GPs, who more commonly discuss patient outcomes on
a regular basis. In future studies the effects of level of
cooperation between pharmacists and GPs on patient out-
comes would be of interest. One pharmacist voluntarily
registered the total time spent per patient, indicating an
average of 145 min per patient with the GP spending an
average of 30 min per patient. Patient consultation took an
average of 30–60 min per patient.
The study protocol had some main requirements about
performing the intervention and data collection (involve-
ment of pharmacist, GP, and patient and the use of the
W-PCP application), but organizational matters were not
described in detail. It was our intention to allow the prac-
tice setting to develop this, as was considered appropriate.
Each site could decide how to plan patient consultations
and discussions of care plans by pharmacist and GP. The
study sites were visited regularly to monitor the progress






t = 0 t = 1 p valuea t = 0 t = 1 p valuea t = 0 t = 1 p valuea
Cardiovascular risk assessment
BPsystolic (mmHg) 143.7 142.3 0.502 139.0 144.6 0.105 144.3 141.5 0.091
BPdiastolic (mmHg) 79.8 76.8 0.008* 79.5 81.6 0.242 77.6 75.9 0.052
Serum LDL-cholesterol (mmol/L) 2.72 2.63 0.337 2.98 2.67 0.740 2.61 2.58 0.032*
Serum HDL-cholesterol (mmol/L) 1.29 1.37 0.021* 1.26 1.37 0.039* 1.30 1.36 0.074
Serum cholesterol (mmol/L) 4.77 4.77 0.976 4.96 4.75 0.986 4.61 4.61 0.193
BMI (kg/m2) 29.8 29.5 0.371 29.9 29.6 0.089 29.9 29.7 0.491
Blood glucose (mmol/L) 6.42 6.56 0.460 6.81 6.51 0.853 6.70 6.72 0.365
HbA1c (mmol/mol) 6.25 6.35 0.213 6.40 6.47 0.226 6.54 6.47 0.582
Safety
Creatinine clearance (mL/min) 65.1 65.4 0.933 62.1 64.7 0.516 69.1 67.8 0.624
Serum sodium (mmol/L) 139.7 139.9 0.575 138.7 139.5 0.282 139.0 139.4 0.244
Serum potassium (mmol/L) 4.2 4.2 0.601 4.3 4.3 0.081 4.2 4.1 0.681
BP, blood pressure; BMI, body mass index
* Sign. (p value\ 0.05)
a Multilevel analysis
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and quality of the study. Main reason for this approach was
to have participating healthcare providers (partly) involved
in the implementation of the study and thereby more
motivated to perform it. A second reason for this approach
was to include the intervention in their daily routine,
hoping the MRs would be continued after completion of
the study. However, since the MRs took up a lot of time
and reimbursement was not available outside the study
setting, none of the study sites did continue with the MRs
after the study was finished. Thus, reimbursement of these
services is essential in order to implement CMRs and PCPs
in daily practice. Moreover, tools need to be developed to
document interventions and to monitor follow-up, which
are easy to implement. These problems related to time,
organization, and funding should be seen in the context of
the small benefit obtained in terms of cardiovascular risk
factors and safety parameters. We question therefore
whether this intervention is actually necessary for all
patients who fit our inclusion criteria. It might be more
suitable for more complex patients with multiple potential
DRPs at baseline. Age and number of medicines used are
not enough to define patients suitable for a CMR. Risk
stratification might be necessary to decide which patients
benefit from a CMR and which patients might benefit
sufficiently from a MR on a lower, more customary level.
Dutch pharmacies all have access to an extensive computer
system where automatic checks are performed on drug–
drug interactions, contraindications, and duplicate medi-
cations. Figure 2 shows that these care issues did not occur
in our study population. Instead, they are all dealt with
during the daily dispensing of medicines, based on the
principle that the pharmacist has approved all dispensed
medications after consulting the patient or prescriber.
Limitations
A lower number of patients than needed for sufficient
power in this study were recruited (512 vs. 800). It was
hard for pharmacists to motivate GPs to participate. More
than 25 pharmacists responded to our letter, but only eight
actually decided to participate. Furthermore, during the
study period it was hard for pharmacists and GPs to per-
form CMRs for all intervention patients due to limited
time. As a consequence, 70 patients (28 %) from the
intervention group had not received any part of the inter-
vention by the end of the study period.
Patients from the control group could have known that
they were allocated to the control group when they were
not invited to make an appointment with their pharmacist
which might have had an impact on their behavior.
We chose a follow-up of 1-year in order for healthcare
providers to have sufficient time to implement proposed
interventions. When multiple interventions are proposed,
healthcare providers may start implementing the most
important one. We did not register the time it took to
implement each individual intervention. We analyzed how
many interventions were implemented after 1-year follow-
up.
In the design of our W-PCP the decision was made to
have ‘‘free text fields’’ for the care plans instead of pre-
defined codes. The main reasons for this were not to bother
healthcare providers too much with additional information
to document, and to prevent differences in interpretation
and coding by different healthcare providers. Therefore,
information from the care plans was coded after the study
period by the researchers. A total of thirty-six potential
harmful DRPs and PCIs were not described properly and
could not be coded. This might have created bias.
Conclusion
Healthcare providers sharing information electronically are
capable of performing integrated care for their patients by
conducting CMRs and developing PCPs. The integrated
use of a CMR with a PCP supports detection and decreases
DRPs and PCIs. However, its benefit in terms of efficacy
and safety parameters is relatively low in a primary, well-
regulated, low-risk population. It might have been more
efficient in terms of outcomes if a higher-risk target group
had been selected.
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